chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Head discomfort, Pain
Clinical narrative: Chills; Fatigue; Head congestion/sinus pain; Body aches; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Apr2021 at 16:45 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Patient had no relevant medical history. Patient previously received penicillin for an unknown indication on an unknown date and experienced allergy. Concomitant medications included cetirizine hydrochloride (ZYRTEC) for an unknown indication from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in Apr2021 at 16:30 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Apr2021 at 16:45, the patient experienced chills, fatigue, head congestion/sinus pain, body aches and dizziness. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care visit. The clinical outcome of the events of chills, fatigue, head pressure, general body pain and dizziness were recovered on an unknown date in 2021.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Muscle spasms, Myalgia, Nausea
Clinical narrative: Severe headache; muscle aches; muscle spasms; mild nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 54-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: EP7533) via an unspecified route of administration in the right arm on 04May2021 at 13:00 (at the age of 54-years-old), as a single dose for COVID-19 immunisation. Medical history included scleroderma. The patient received an unspecified concomitant medications.  The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: EP7533) via an unspecified route of administration in the right arm on 13April2021 at 13:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 04May2021 at 23:00, after the vaccination, the patient experienced severe headache, muscle aches, muscle spasms, mild nausea. The clinical outcome of the events severe headache, muscle aches, muscle spasms, and mild nausea was recovering at the time of the report.  No follow-up attempts are possible. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Hyperhidrosis, Lymphadenopathy, Pain in extremity, Peripheral swelling
Clinical narrative: swelling in arm pit noticed on self examination; excess sweating on left arm pit after minor exercise; Lymph Nodes swelling; soreness in left arm and left arm pit; soreness in left arm and left arm pit; Slight fever; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 03May2021 at 15:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included pre-diabetes. The patient did not receive concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0161) via an unspecified route of administration in the left arm on 16Apr2021 at 15:45 as a single dose for COVID-19 immunisation. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04May2021, the patient experienced lymph node swelling, soreness in left arm and left arm pit and slight fever. On 05May2021, the patient experienced swelling in armpit on self examiniation and excess sweating on left arm pit after minor exercise. On 06May2021, in the morning swelling increased and soreness. The patient took paracetamol (TYLENOL) 250 mg and the swelling decreased in the evening. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with paracetamol (TYLENOL). The clinical outcomes of the events lymph nodes swelling, soreness in left arm and left arm pit, slight fever, swelling in armpit and excess sweating on left arm pit were resolving at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: swelling in arm pit noticed on self examination; excess sweating on left arm pit after minor exercise; Lymph Nodes swelling; soreness in left arm and left arm pit; soreness in left arm and left arm pit; Slight fever; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 03May2021 at 15:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included pre-diabetes. The patient did not receive concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0161) via an unspecified route of administration in the left arm on 16Apr2021 at 15:45 as a single dose for COVID-19 immunisation. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04May2021, the patient experienced lymph node swelling, soreness in left arm and left arm pit and slight fever. On 05May2021, the patient experienced swelling in armpit on self examiniation and excess sweating on left arm pit after minor exercise. On 06May2021, in the morning swelling increased and soreness. The patient took paracetamol (TYLENOL) 250 mg and the swelling decreased in the evening. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with paracetamol (TYLENOL). The clinical outcomes of the events lymph nodes swelling, soreness in left arm and left arm pit, slight fever, swelling in armpit and excess sweating on left arm pit were resolving at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Malaise, Rash papular, Rash pruritic
Clinical narrative: Itchy painful raised rash on arm.; Painful swollen glands around neck and clavicle.; Malaise; Itchy painful raised rash on arm.; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration in the left arm on 04May2021 at 12:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, kidney disease and COVID-19. The patient had no known allergies to medications, food, or other products. The patient received unspecified concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176)  via an unspecified route of administration in the left arm on 11Mar2021 at 15:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05May2021 at 06:00, the patient experienced itchy painful raised rash on arm that progressively became larger over 48 hours, painful swollen glands around neck and clavicle and malaise. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events itchy painful raised rash on arm that progressively became larger over 48 hours, painful swollen glands around neck and clavicle and malaise was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Fatigue, Headache, Vaccination site pain
Clinical narrative: Injection site soreness (arm pain); headache; chest tightness; tiredness; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 05May2021 at 12:15 as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included loratadine (MANUFACTURER UNKNOWN), drospirenone (MANUFACTURER UNKNOWN), ethinylestradiol (MANUFACTURER UNKNOWN) and levetiracetam (LEV); all for unknown indication and from an unknown start date. The patient had no known allergies to food, medications or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 14Apr2021 at 12:15 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 06May2021, the patient experienced injection site soreness (arm pain), headache, chest tightness and tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events injection site soreness (arm pain), headache, chest tightness and tiredness were recovering at the time of the report.  No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Hordeolum
Clinical narrative: Stye in left eye; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 15:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included shellfish allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021, the next day after the vaccination, the patient had stye in left eye. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measure was taken as a result of the event and included treatment with antibiotic ointment. The clinical outcome of the event stye in left eye was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Vertigo positional
Clinical narrative: Vertigo from positional changes; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0171), via an unspecified route of administration in the right arm on 24Apr2021 at 13:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient reported that he was a smoker. The patient had no known allergies to medications, food or other products. The patient did not receive any medication within two weeks of the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8734), via an unspecified route of administration in the right arm on an unspecified date as a single dose for COVID-19 immunisation. On 25Apr2021 at 09:00, the morning after the second dose, the patient experienced vertigo from positional changes. The patient reported that it had been 2 weeks since his second dose and the vertigo still remained but varied in how bad it was. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the event vertigo from positional changes which included treatment with meclizine. The clinical outcome of the event vertigo from positional changes was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Abdominal distension, Splenomegaly
Clinical narrative: I think I have an enlarged spleen.; I feel constantly bloated and full; I feel constantly bloated and full; This is a spontaneous report from a non-contactable consumer, the patient. A patient of unknown age and unknown gender received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 05May2021 at 16:30 as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not take any concomitant medication. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 14Apr2021 at 04:30 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  On 06May2021 at 05:00 the patient thought the patient had an enlarged spleen and the patient feel constantly bloated and full. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event enlarged spleen, felt constantly bloated and full were not recovered.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Dysgeusia
Clinical narrative: Metallic taste; loss of taste; loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 05May2021 at 15:45 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included paracetamol (TYLENOL) from an unknown date, for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN)  via an unspecified route of administration in the right arm on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05May2021 the patient experienced Metallic taste, loss of taste and loss of smell. The patient reported that he felt Metallic taste immediately after and a few hours later loss of taste and smell. No therapeutic measures were taken as a result of the adverse event. The clinical outcome of the event Metallic taste, loss of taste, loss of smell was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 65.0
Sex: U
Vaccine: COVID19
Symptoms: Blood pressure increased, Blood pressure measurement, Dizziness, Heart rate, Oxygen saturation
Clinical narrative: feels dizzy while sitting; blood pressure was elevated; This is a spontaneous report from a contactable pharmacist. A 65-year-old unknown gender patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EI9261) via intramuscular route of administration in the arm left on 09Feb2021 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, diverticulitis, penicillin allergy and syncope 2 days prior to the vaccine. Concomitant medications included sodium picosulfate (DULCOLAX). The patient previously received ciprofloxacin (MANUFACTURER UNKNOWN) for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Feb2021, the patient felt dizzy while sitting. His blood pressure was elevated at 179/100 mmHg. Heart rate and oxygen saturation were within normal limits. Retook blood pressure a second time 165/91 mmHg. Third blood pressure 165/87 mmHg. Fourth blood pressure 164/84 mmHg. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events felt dizzy while sitting and blood pressure elevated were recovered on unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Hearing - started off like echoing, got worse and became constant ringing.  Lasted about 5 days; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0162) via an unspecified route of administration in the left arm on 13Apr2021(at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to lobster. Concomitant medications included amoxicillin, clavulanic acid (AMOXCLAV) 875 mg and pseudoephedrine hydrochloride (SUDAFED), all from unknown dates and for unknown indications. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP6955) via an unspecified route of administration in the left arm on 16Mar2021(at the age of 55-year-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 21Apr2021, the patient experienced hearing which started off like echoing which got worse and became constant ringing. The adverse event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported event. The clinical outcome of the event hearing started off like echoing which got worse and became constant ringing lasted for about 5 days and was resolved on an unknown date in Apr 2021.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pruritus, Eye swelling, Ocular hyperaemia, Periorbital swelling
Clinical narrative: they are red; They feel itchy; my eyes started swelling a lot. They were huge!; my eyes were puffy; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 04May2021 at 15:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and did not receive any concomitant medications. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on an unknown date (at the age of 33-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 05May2021 at 06:45, when the patient woke up 15 hours after the shot, eyes were puffy. On 05May2021 at 13:45, 22 hours after the shot, the eyes started swelling a lot. They were huge. On 06May2021 at 15:45, 48 hours after the shot, the swelling had subsided a little and they were red and they felt itchy. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events eyes were puffy, they were red and they felt itchy was not resolved while the outcome of the event eyes started swelling a lot was resolving at the time of report.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster, Lymphadenopathy, Pain
Clinical narrative: shingles rash; soreness; swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 14Apr2021 at 12:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. It was unknown if the patient had any allergies to medications, food or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ENG6199) via an unspecified route of administration in the left arm on 24Mar2021 at 12:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 12:00, the patient got shingles. Started with soreness and swollen lymph nodes and then shingles rash. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatments for the events. The clinical outcome of the events soreness, swollen lymph nodes and shingles rash was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Decreased appetite, Fatigue, Feeding disorder, Headache, Heart rate increased
Clinical narrative: Heartrate increased; Could not eat; Sleepiness increased each day; Loss of appetite; Tiredness; Headache; Fever off/on; Nausea kept me from eating; Vomit; This is a spontaneous report from a contactable consumer, the patient. A 25-years-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the right leg on an unknown date in Apr2021 at 18:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included born with Pallister-Killian tetrasomy 12p, history of physical and cognitive delays, seizures, GERD (gastroesophageal reflux disease). The patient had known allergies to wheat, squash, cats and dogs with long fur. Concomitant medications included KEPPRA, lamotrigine (MANUFACTURER UNKNOWN), esomeprazole (MANUFACTURER UNKNOWN) and clorazepate (MANUFACTURER UNKNOWN)for an unknown indication, from an unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On an unknown date in Apr2021 at 08:00, the patient experienced heartrate increased at times, could not eat, sleepiness increased each day, loss of appetite, tiredness, headache, fever off/on, nausea and vomit. It was reported that nausea was worst and kept from eating. The patient did vomit twice and could not eat for 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported events. The clinical outcome of heartrate increased, could not eat, sleepiness, loss of appetite, tiredness, headache, fever off/on, nausea and vomit was recovering.    No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, Somnolence, Vomiting
Clinical narrative: Heartrate increased; Could not eat; Sleepiness increased each day; Loss of appetite; Tiredness; Headache; Fever off/on; Nausea kept me from eating; Vomit; This is a spontaneous report from a contactable consumer, the patient. A 25-years-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the right leg on an unknown date in Apr2021 at 18:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included born with Pallister-Killian tetrasomy 12p, history of physical and cognitive delays, seizures, GERD (gastroesophageal reflux disease). The patient had known allergies to wheat, squash, cats and dogs with long fur. Concomitant medications included KEPPRA, lamotrigine (MANUFACTURER UNKNOWN), esomeprazole (MANUFACTURER UNKNOWN) and clorazepate (MANUFACTURER UNKNOWN)for an unknown indication, from an unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On an unknown date in Apr2021 at 08:00, the patient experienced heartrate increased at times, could not eat, sleepiness increased each day, loss of appetite, tiredness, headache, fever off/on, nausea and vomit. It was reported that nausea was worst and kept from eating. The patient did vomit twice and could not eat for 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported events. The clinical outcome of heartrate increased, could not eat, sleepiness, loss of appetite, tiredness, headache, fever off/on, nausea and vomit was recovering.    No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Pain in extremity
Clinical narrative: Aches; Chills; Arm pain; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) in the left arm on an unknown date as a single dose and also received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) in the left arm on an unknown date as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had a history of allergy to penicillin. The patient received buspirone15 mg (MANUFACTURER UNKNOWN) within 2 weeks of vaccination for an unknown indication. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. On an unknown date, the patient had experienced aches, chills, arm pain and fatigue. The patient did not receive any treatment for the reported events. The clinical outcome of the events aches, chills, arm pain and fatigue was resolving at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Dizziness, Fatigue, Headache, Laboratory test
Clinical narrative: Severe headaches; Dizziness; Tired all the time; Muscle weakness; muscle pain all day long; some chest tightness; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the right arm on 22Apr2021 at 08:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included Monoclonal Gammopathy of Undetermined Significance (MGUS), neuropathy, myasthenia gravis, high cholesterol, high blood pressure, hypoglycemia, gastroesophageal reflux disease (GERD) and cataracts. The patient had unspecified allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 22:30, the patient experienced severe headaches, dizziness, was tired all the time, muscle weakness and pain all day long and some chest tightness. The patient stated that, the headaches were so bad that patient could not think straight. The events resulted in doctor or other healthcare professional office/clinic visit. The patient underwent unspecified lab tests on an unknown date and the results were unknown. The clinical outcome of the events severe headaches, dizziness, tired all the time, muscle weakness and pain all day long and some chest tightness were not resolved at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Muscular weakness, Myalgia
Clinical narrative: Severe headaches; Dizziness; Tired all the time; Muscle weakness; muscle pain all day long; some chest tightness; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the right arm on 22Apr2021 at 08:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included Monoclonal Gammopathy of Undetermined Significance (MGUS), neuropathy, myasthenia gravis, high cholesterol, high blood pressure, hypoglycemia, gastroesophageal reflux disease (GERD) and cataracts. The patient had unspecified allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 22:30, the patient experienced severe headaches, dizziness, was tired all the time, muscle weakness and pain all day long and some chest tightness. The patient stated that, the headaches were so bad that patient could not think straight. The events resulted in doctor or other healthcare professional office/clinic visit. The patient underwent unspecified lab tests on an unknown date and the results were unknown. The clinical outcome of the events severe headaches, dizziness, tired all the time, muscle weakness and pain all day long and some chest tightness were not resolved at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: period was late by more than a week; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 24Apr2021 at 11:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient was reported as none and was perfectly healthy. Patient did not receive any other medications within 2 weeks of vaccination. Patient did not take any medications in the past. The patient had no known allergies to food, medications or other products. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in May2021, the patient experienced period that was late by more than a week. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event period that was late by more than a week was recovered at the time of report.   No follow-up attempts are possible. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure diastolic decreased, Blood pressure measurement, Body temperature, Chest discomfort, Heart rate
Clinical narrative: Mild chest tightness; Blood pressure 127/66; This is a spontaneous report from a contactable pharmacist. A 49-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an intramuscular route of administration in the left arm on 19Apr2021 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medication included blood pressure medication (UNKNOWN MANUFACTURER) from unknown date for blood pressure. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via an unspecified route of administration in the left arm on 29Mar2021, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021 the patient experienced mild chest tightness and blood pressure 127/66 (unspecified units). The patient did not receive any treatment for the event. Patient did not visit to the doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care for adverse events. On 19Apr2021, the patient underwent tests for blood pressure and the result was 127/66 (unspecified units), heart rate was 65 (unspecified units), oxygen saturation was 96%, and body temperature was 36.5C. The reporter reported that patient experienced mild chest tightness, but stated she did not take medications for blood pressure in the morning of the vaccination. At 09:53 her blood pressure was 127/66, heart rate 65; O2 saturation 96%, temperature 36.5C; she denied need for higher level of care. She reported that she will take blood pressure medication with hydration once she leaves hospital vaccine clinic. She left at 10:20 symptom free. The clinical outcome of the events chest tightness and blood pressure 127/66 was recovered on 19Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Oxygen saturation
Clinical narrative: Mild chest tightness; Blood pressure 127/66; This is a spontaneous report from a contactable pharmacist. A 49-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an intramuscular route of administration in the left arm on 19Apr2021 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medication included blood pressure medication (UNKNOWN MANUFACTURER) from unknown date for blood pressure. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via an unspecified route of administration in the left arm on 29Mar2021, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021 the patient experienced mild chest tightness and blood pressure 127/66 (unspecified units). The patient did not receive any treatment for the event. Patient did not visit to the doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care for adverse events. On 19Apr2021, the patient underwent tests for blood pressure and the result was 127/66 (unspecified units), heart rate was 65 (unspecified units), oxygen saturation was 96%, and body temperature was 36.5C. The reporter reported that patient experienced mild chest tightness, but stated she did not take medications for blood pressure in the morning of the vaccination. At 09:53 her blood pressure was 127/66, heart rate 65; O2 saturation 96%, temperature 36.5C; she denied need for higher level of care. She reported that she will take blood pressure medication with hydration once she leaves hospital vaccine clinic. She left at 10:20 symptom free. The clinical outcome of the events chest tightness and blood pressure 127/66 was recovered on 19Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose, Blood glucose increased
Clinical narrative: Blood glucose level 280; This is a spontaneous report from a contactable pharmacist. A 46-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the left arm on 29Apr2021 (at the age of 46-years-old), as a single dose for COVID-19 immunisation. Medical history included diabetes, dizziness and feeling sick. The patient did not have any allergies to medications, food or other products. Concomitant medications included metformin (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. On 29Apr2021, the patient experienced blood glucose level 280. Denies symptoms of active illness. The patient stated that would be more cautious and take the prescribed medications. Therapeutic measures were not taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient underwent lab test and procedure which included blood glucose and the result was shown as 280 (units unspecified). The clinical outcome of the event blood glucose level 280 was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Paraesthesia, Pruritus, Rash
Clinical narrative: Shingles; Tingling; Itching; Rash appeared on my back and got worse over a few days; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ewo175) via an unspecified route of administration in the left arm on 28Apr2021 at 12:30 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included loratadine (CLARITIN) and RITUAL multivitamin. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took penicillin and experienced allergy. The patient previously also received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8729) via an unspecified route of administration in the left arm on an unknown date in Apr2021 at 15:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. On 03May2021, a few days after the injection on Monday, the patient noticed itching, tingling, a rash appeared on the back, got worse over a few days and patient also stated it was a possible case of shingles. On 06May2021, the patient visited her dermatologist and he suspected shingles. On an unknown date in May2021, the patient underwent viral test done to confirm shingles and results were unknown. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with antiviral. The clinical outcome of the events shingles, itching, tingling and rash was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Chronic headaches; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old, non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7533) via an unspecified route of administration in left arm on 02Apr2021 at 11:30 (at an age of 51-year-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0171) via an unspecified route route of administration in left arm on 28Apr2021 at 11:30 (at an age of 51-year-old) as single dose for COVID-19 immunisation. Medical history included allergy towards some antibiotics (not specified). Concomitant medication included diclofenac (MANUFACTURER UNKNOWN), multivitamins (MANUFACTURER UNKNOWN), acetylsalicylic acid (ASPIRIN) and cannabidiol (CBD) oil (MANUFACTURER UNKNOWN) . The patient did not receive any other vaccination within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Apr2021, in the few days following vaccination, the patient experienced chronic headaches. The patient had headaches as side effect of vaccine and was continuing to have bad headaches daily 8 days after second dose. Therapeutic measures were not taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event of chronic headaches was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Moderate rash on chest, torso, and armpits.; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 29Apr2021 at 08:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 08Apr2021 at 07:45 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 30Apr2021, the patient experienced moderate rash on chest, torso and armpits. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event moderate rash on chest, torso and armpits was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: tinnitus; This is a spontaneous report from a contactable physician. A 77-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN, not available/provided to reporter at the time of report completion) via an unspecified route of administration on an unknown date (at the age of 77-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date the patient experienced tinnitus. The clinical outcome of the event tinnitus was unknown at the time of this report.   No follow-up attempts are needed; information about lot number cannot be obtained. No further information is expected.